Australia is showing great interest in the introduction of Retatrutide, a novel medication by Novo Nordisk. This combined-action drug, targeting both GLP-1 and GIP receptors, demonstrates significant efficacy in https://sociallytraffic.com/story7010980/this-new-drug-retatrutide-australia-a-potential-advancement-for-obesity-treatment